Related Experiment Video

Updated: Apr 28, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.3K

Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth

Takashi Nomiyama1, Takako Kawanami1, Shinichiro Irie2

  • 1Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, Jonan-ku, Fukuoka, Japan.

Diabetes
|June 1, 2014
PubMed

Insights

The incretin drug exendin-4 (Ex-4) shows promise in fighting prostate cancer. This glucagon-like peptide-1 receptor (GLP-1R) agonist inhibits cancer cell growth and reduces tumor size by affecting key signaling pathways.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Incretin therapies offer benefits beyond glycemic control, but their anticancer effects are under-explored.
  • Prostate cancer is a significant cause of mortality in diabetic patients.

Purpose of the Study:

  • To investigate the effects of exendin-4 (Ex-4), a GLP-1 receptor (GLP-1R) agonist, on prostate cancer.
  • To determine the underlying mechanisms of Ex-4's action on prostate cancer cells.

Main Methods:

  • Examined GLP-1R expression in human prostate cancer tissues.
  • Assessed Ex-4's effect on prostate cancer cell proliferation in vitro using various cell lines.
  • Investigated the role of GLP-1R in Ex-4's antiproliferative activity via antagonists and siRNA.
  • Analyzed Ex-4's impact on androgen receptor activation, apoptosis, and ERK-MAPK signaling.
  • Evaluated Ex-4's efficacy in a mouse xenograft model of prostate cancer.

Main Results:

  • GLP-1R expression was found to colocalize with P504S, a prostate cancer marker.
  • Ex-4 significantly inhibited the proliferation of LNCap, PC3, and DU145 prostate cancer cell lines, dependent on GLP-1R expression.
  • Ex-4 decreased extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) phosphorylation in LNCap cells.
  • In vivo, Ex-4 attenuated prostate cancer growth and reduced tumor expression of P504S, Ki67, and phosphorylated ERK-MAPK.

Conclusions:

  • Exendin-4 demonstrates significant antiproliferative and tumor-attenuating effects on prostate cancer.
  • The anticancer activity of Ex-4 is mediated through the inhibition of the ERK-MAPK signaling pathway.
  • These findings suggest potential therapeutic applications for GLP-1R agonists in prostate cancer treatment.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K